Silobreaker.com
360° SearchNetworkHot SpotsTrends
 
Advanced Search Options >>
Saturday, November 21, 2009 8:54 AM

Published 11/06/2009 by Nasdaq


Biogen Updates Tysabri Label To Reflect Risk With Longer Use

NEW YORK -(Dow Jones)- Biogen Idec Inc. (BIIB) amended the U.S. label of multiple sclerosis treatment Tysabri, sold with Elan Corp. PLC (ELN), on Friday to reflect that the risk of a rare brain infection rises with longer usage.

The changes, which were expected, note that the occurrence...

Share this 

There are no more reports on this story yet.

Quotes

"We do not expect physicians to significantly change their Tysabri prescribing habits in the near-term" Sendek said in a research...
Network

Blogs

sort by: Date | Relevance
When Rival Drug Makers Compare Notes On Safety ... [WSJ.com: Health Blog - 11/11/2009]
Roche, Elan and Biogen are going to team up to study why some patients taking certain drugs develop a rare brain infection called PML. This sort of thing has happened ...
1

  •  
  •  
  •